The South Korea Paroxysmal Nocturnal Haemoglobinuria (PNH) Market size stood at around USD xx billion in 2019 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare acquired, life-threatening disease of the blood. PNH occurs when mutations of a gene called PIG-A occur in a bone marrow stem cell. The disease is characterized by destruction of red blood cells, blood clots, and impaired bone marrow function. PNH affects 1-1.5 persons per million of the population and is primarily a disease of younger adults. The median age of diagnosis is 35-40 years of age, with occasional cases diagnosed in childhood or adolescence. PNH is closely related to aplastic anaemia. In fact, up to 30% of newly diagnosed cases of PNH evolve from aplastic anaemia. The median survival after diagnosis is 10 years; however, some patients can survive for decades with only minor symptoms.
Emergence of biologics that target causal haemolytic defect or abnormal hematopoietic stem cell will boosting the market growth. For instance, Samsung Bioepis, a joint venture between Samsung Biologics and Biogen, will begin a clinical study to develop a biosimilar for Soliris used to treat PNH. Other factors like increasing prevalence of blood disorders, high unmet demand for drugs, rise in investment for the development of novel drugs are also driving the market growth.